News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.3638871622816 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost (zacks.com)
- Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22 (streetinsider.com)
- Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn? (finance.yahoo.com)
- Achillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS (americanbankingnews.com)
- Achillion Pharmaceuticals (ACHN) Updates FY18 Earnings Guidance (americanbankingnews.com)
ACHN has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Monday, November 6th. Leerink Swann restated a “buy” rating and set a $5.00 price objective on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. BidaskClub upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Finally, B. Riley assumed coverage on Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 price target for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.89.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). During the same period in the prior year, the company posted ($0.03) earnings per share. sell-side analysts forecast that Achillion Pharmaceuticals will post -0.6 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals (NASDAQ:ACHN) Receives News Impact Rating of 0.19” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/02/23/achillion-pharmaceuticals-achn-earns-daily-news-sentiment-rating-of-0-19.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.